Skip to main content
Top

11-03-2024 | Colonoscopy | Original Article—Alimentary Tract

Prevalence of colonoscopy in Japan using a large-scale health claims data compared to esophagogastroduodenoscopy

Authors: Naohisa Yoshida, Ayako Maeda-Minami, Hideki Ishikawa, Michihiro Mutoh, Yuri Tomita, Reo Kobayashi, Hikaru Hashimoto, Ken Inoue, Ryohei Hirose, Osamu Dohi, Yoshito Itoh, Yasunari Mano

Published in: Journal of Gastroenterology

Login to get access

Abstract

Objective

Prevalence of colonoscopy (CS) is an important countermeasure against colorectal cancer (CRC). In this study, we used large-scale data for a comparison of CS with esophagogastroduodenoscopy (EGD) in Japan.

Methods

This was a retrospective descriptive study. Commercially anonymized patient data were collected from various health insurance societies (JMDC, Inc. Tokyo, Japan) generated from the insurance registry, receipts (inpatient, outpatient, and prescription), and health checkup data. The data also included healthy subjects who had never been examined in a hospital. The data of 2,760,048 persons who were 50–75 years old during January 2012–December 2019 were extracted from the original data source. The annual rate, the prevalence rate (frequency of those undergoing at least one endoscopy during the period), and the percentage of repeaters (undergoing endoscopy at least twice during the period) of CS were calculated and compared to those of EGD.

Results

The annual rates in 2012/2015/2019 were 3.4%/4.5%/5.3% for CS, respectively, and increased gradually from 2012 to 2019. Those rates were 7.0%/7.9%/7.4% for EGD, respectively, and did not increase. The prevalence rates of CS and EGD were 25.3% and 36.2%, respectively, among the 137,246 participants over 8 years. The prevalence rates of individuals in their 50 s/60 s/70 s were 23.0%/25.9%/31.4% for CS and 33.0%/37.6%/40.7% for EGD, respectively. The proportions of males/females were 27.9%/20.7% for CS, and 36.4%/35.8% for EGD, respectively. The repeat rates of CS and EGD were 40.3% and 44.8%, respectively, over 8 years.

Conclusions

Using large-scale data, we determined the status of CS and EGD in Japan.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
2.
go back to reference Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095–105.CrossRefPubMed Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095–105.CrossRefPubMed
3.
go back to reference Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013;158:312–20.CrossRefPubMedPubMedCentral Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013;158:312–20.CrossRefPubMedPubMedCentral
4.
go back to reference Davidson KW, Barry MJ, United States Preventive Services Task Force, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:1965–77.CrossRefPubMed Davidson KW, Barry MJ, United States Preventive Services Task Force, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:1965–77.CrossRefPubMed
7.
go back to reference Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73.CrossRefPubMed Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73.CrossRefPubMed
9.
go back to reference Ross WA. Colorectal cancer screening in evolution: Japan and the USA. J Gastroenterol Hepatol. 2010;25:S49-56.CrossRefPubMed Ross WA. Colorectal cancer screening in evolution: Japan and the USA. J Gastroenterol Hepatol. 2010;25:S49-56.CrossRefPubMed
10.
go back to reference Yoneda M, Yamamoto T, Honda Y, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56:1022–32.CrossRefPubMedPubMedCentral Yoneda M, Yamamoto T, Honda Y, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56:1022–32.CrossRefPubMedPubMedCentral
11.
go back to reference Umemura T, Wattanakamolkul K, Nakayama Y, et al. Real-world epidemiology, clinical and economic burden of chronic hepatitis B in Japan: a retrospective study using JMDC claims database. Infect Dis Ther. 2023;12:1337–49.CrossRefPubMedPubMedCentral Umemura T, Wattanakamolkul K, Nakayama Y, et al. Real-world epidemiology, clinical and economic burden of chronic hepatitis B in Japan: a retrospective study using JMDC claims database. Infect Dis Ther. 2023;12:1337–49.CrossRefPubMedPubMedCentral
12.
go back to reference Yoshida N, Mano Y, Matsuda T, et al. Complications of colonoscopy in Japan: an analysis using large-scale health insurance claims data. J Gastroenterol Hepatol. 2021;36:2745–53.CrossRefPubMed Yoshida N, Mano Y, Matsuda T, et al. Complications of colonoscopy in Japan: an analysis using large-scale health insurance claims data. J Gastroenterol Hepatol. 2021;36:2745–53.CrossRefPubMed
13.
go back to reference Yoshida N, Maeda-Minami A, Ishikawa H, et al. Analysis of the development of gastric cancer after resecting colorectal lesions using large-scale health insurance claims data. J Gastroenterol. 2023;58:1105–13.CrossRefPubMed Yoshida N, Maeda-Minami A, Ishikawa H, et al. Analysis of the development of gastric cancer after resecting colorectal lesions using large-scale health insurance claims data. J Gastroenterol. 2023;58:1105–13.CrossRefPubMed
14.
go back to reference Helsingen LM, Kalager M. Colorectal cancer screening—approach, evidence, and future directions. NEJM Evidence. 2022;1:EVIDra2100035.CrossRefPubMed Helsingen LM, Kalager M. Colorectal cancer screening—approach, evidence, and future directions. NEJM Evidence. 2022;1:EVIDra2100035.CrossRefPubMed
15.
go back to reference Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: an update. World J Gastroenterol. 2017;23:3632–42.CrossRefPubMedPubMedCentral Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: an update. World J Gastroenterol. 2017;23:3632–42.CrossRefPubMedPubMedCentral
16.
go back to reference Helsingen LM, Vandvik PO, Jodal HC, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019;367: l5515.CrossRefPubMed Helsingen LM, Vandvik PO, Jodal HC, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019;367: l5515.CrossRefPubMed
17.
go back to reference Kaminski MF, Kraszewska E, Rupinski M, Laskowska M, Wieszczy P, Regula J. Design of the polish colonoscopy screening program: a randomized health services study. Endoscopy. 2015;47:1144–50.CrossRefPubMed Kaminski MF, Kraszewska E, Rupinski M, Laskowska M, Wieszczy P, Regula J. Design of the polish colonoscopy screening program: a randomized health services study. Endoscopy. 2015;47:1144–50.CrossRefPubMed
18.
go back to reference von Karsa L, Patnick J, European Colorectal Cancer Screening Guidelines Working Group, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45:51–9. von Karsa L, Patnick J, European Colorectal Cancer Screening Guidelines Working Group, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45:51–9.
19.
go back to reference Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;152:1217-37.e3.CrossRefPubMed Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;152:1217-37.e3.CrossRefPubMed
20.
go back to reference Bretthauer M, Kaminski MF, Løberg M, et al. Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial. JAMA Intern Med. 2016;176:894–902.CrossRefPubMedPubMedCentral Bretthauer M, Kaminski MF, Løberg M, et al. Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial. JAMA Intern Med. 2016;176:894–902.CrossRefPubMedPubMedCentral
21.
go back to reference Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.CrossRefPubMed Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.CrossRefPubMed
22.
go back to reference Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med. 2022;387:1547–56.CrossRefPubMed Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med. 2022;387:1547–56.CrossRefPubMed
23.
go back to reference Senore C, Inadomi J, Segnan N, Bellisario C, Hassan C. Optimising colorectal cancer screening acceptance: a review. Gut. 2015;64:1158–77.CrossRefPubMed Senore C, Inadomi J, Segnan N, Bellisario C, Hassan C. Optimising colorectal cancer screening acceptance: a review. Gut. 2015;64:1158–77.CrossRefPubMed
24.
go back to reference Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.CrossRefPubMed Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.CrossRefPubMed
25.
go back to reference Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844–57.CrossRefPubMed Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844–57.CrossRefPubMed
26.
go back to reference Hassan C, Quintero E, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2013;45:842–51.CrossRefPubMed Hassan C, Quintero E, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2013;45:842–51.CrossRefPubMed
27.
go back to reference Matsuda T, Fujii T, Sano Y, et al. Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy: the Japan Polyp Study Workgroup. Gut. 2021;70:1469–78.CrossRef Matsuda T, Fujii T, Sano Y, et al. Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy: the Japan Polyp Study Workgroup. Gut. 2021;70:1469–78.CrossRef
28.
go back to reference Martínez ME, Thompson P, Messer K, et al. One-year risk for advanced colorectal neoplasia: U.S. versus U.K. risk-stratification guidelines. Ann Intern Med. 2012;157:856–64.CrossRefPubMedPubMedCentral Martínez ME, Thompson P, Messer K, et al. One-year risk for advanced colorectal neoplasia: U.S. versus U.K. risk-stratification guidelines. Ann Intern Med. 2012;157:856–64.CrossRefPubMedPubMedCentral
29.
go back to reference Yoshida N, Naito Y, Siah KT, et al. High incidence of metachronous advanced adenoma and cancer after endoscopic resection of colon polyps ≥20 mm in size. Dig Endosc. 2016;28:194–202.CrossRefPubMed Yoshida N, Naito Y, Siah KT, et al. High incidence of metachronous advanced adenoma and cancer after endoscopic resection of colon polyps ≥20 mm in size. Dig Endosc. 2016;28:194–202.CrossRefPubMed
30.
go back to reference Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.CrossRefPubMed Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.CrossRefPubMed
Metadata
Title
Prevalence of colonoscopy in Japan using a large-scale health claims data compared to esophagogastroduodenoscopy
Authors
Naohisa Yoshida
Ayako Maeda-Minami
Hideki Ishikawa
Michihiro Mutoh
Yuri Tomita
Reo Kobayashi
Hikaru Hashimoto
Ken Inoue
Ryohei Hirose
Osamu Dohi
Yoshito Itoh
Yasunari Mano
Publication date
11-03-2024
Publisher
Springer Nature Singapore
Published in
Journal of Gastroenterology
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-024-02087-x
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.